Related references
Note: Only part of the references are listed.
Article
Public, Environmental & Occupational Health
Takaaki Kobayashi et al.
Summary: This study describes COVID-19 cases among nonphysician healthcare personnel (HCP) by their work location. The highest proportion of HCP with COVID-19 was found in the emergency department, while the lowest proportion was among those working remotely. COVID-19 and non-COVID-19 units had similar proportions of HCP with COVID-19 (13%). Cases decreased across all work locations following COVID-19 vaccination.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
(2023)
Article
Medicine, General & Internal
Iftikhar Nadeem et al.
Summary: The study aimed to assess the safety and efficacy of the Sinopharm COVID-19 vaccine in the Pakistani adult population aged 60 or above. The results showed that the vaccine significantly reduced the risk of symptomatic infection, hospitalizations, and mortality among vaccinated individuals.
POSTGRADUATE MEDICAL JOURNAL
(2023)
Article
Medicine, General & Internal
Min Kang et al.
Summary: Retrospective cohort study suggests that full vaccination with inactivated vaccines is effective against the B.1.617.2 variant, providing protection against infections, symptomatic infections, pneumonia, and severe or critical illness. Partial vaccination shows limited effectiveness.
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Infectious Diseases
Zoltan Voko et al.
Summary: This observational study in Hungary estimated the effectiveness of five different vaccines in preventing SARS-CoV-2 infection and COVID-19-related death, and found that these vaccines have high or very high effectiveness in these areas.
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Article
Biochemistry & Molecular Biology
Thiago Cerqueira-Silva et al.
Summary: This Brazilian study aimed to estimate the effectiveness of CoronaVac and a booster dose of BNT162b2 vaccine against COVID-19 infection and severe outcomes. The study found that CoronaVac had a 55% effectiveness against infection and 82.1% effectiveness against severe outcomes 14-30 days after the second dose. However, the effectiveness decreased to 34.7% against infection and 72.5% against severe outcomes over 180 days after the second dose. A BNT162b2 booster dose administered 6 months after CoronaVac improved the effectiveness to 92.7% against infection and 97.3% against severe outcomes. Older individuals had lower protection after the second dose but similar protection after the booster.
Article
Biochemistry & Molecular Biology
Jingxin Li et al.
Summary: The study suggests that additional COVID-19 vaccine doses may be needed for individuals who initially received CoronaVac. Heterologous boosting with Convidecia, a recombinant adenovirus type 5 (AD5)-vectored vaccine, was found to be safe and more immunogenic than homologous boosting with CoronaVac in adults previously vaccinated with CoronaVac.
Article
Medicine, General & Internal
Roos S. G. Sablerolles et al.
Summary: This study investigated the immunogenicity and reactogenicity of a homologous or heterologous booster in healthcare workers who had received a single-shot Ad26.COV2.S vaccine. The results showed that booster vaccinations increased the levels of S-specific binding antibodies, neutralizing antibodies, and T-cell responses compared to a single Ad26.COV2.S vaccination. Boosters containing mRNA-based vaccines induced significantly higher levels of binding antibodies than homologous boosters. The mRNA-1273 booster was the most immunogenic but had higher reactogenicity compared to the BNT162b2 and Ad26.COV2.S boosters. Local and systemic reactions were generally mild to moderate in the first 2 days after booster administration.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Farida Ismail AlHosani et al.
Summary: This community-based observational study found that the BBIBP-CorV inactivated vaccine is effective in preventing severe COVID-19 outcomes such as hospital admissions and death. Fully vaccinated individuals showed higher protection compared to partially vaccinated individuals.
Article
Immunology
Paskorn Sritipsukho et al.
Summary: During the period when the delta variant was dominant, the two-dose CoronaVac plus one BNT162b2 or ChAdOx1 nCoV-19 booster regimens were highly effective in preventing COVID-19.
EMERGING MICROBES & INFECTIONS
(2022)
Review
Medicine, General & Internal
Baoqi Zeng et al.
Summary: This study conducted a systematic review and meta-analysis to assess the effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern (VOC). The results showed that full vaccination was highly effective against the Alpha variant and moderately effective against the Beta, Gamma, and Delta variants. Booster vaccination was more effective against the Delta and Omicron variants. mRNA vaccines appeared to have higher effectiveness against the VOC compared to other vaccines.
Article
Infectious Diseases
Jing Lian Suah et al.
Summary: This study investigated the waning vaccine effectiveness (VE) of BNT162b2 and CoronaVac vaccines against COVID-19 infection, ICU admission, and death. The results showed that the VE of BNT162b2 against COVID-19 infection decreased from 90.8% to 79.3% over time, while the VE against ICU admission and death remained stable. For CoronaVac, the VE against COVID-19 infection declined from 74.5% to 30.4%, and the effectiveness against ICU admission also decreased. The study concludes that the VE against COVID-19 infection decreases after 3-5 months of full vaccination for both BNT162b2 and CoronaVac vaccines in Malaysia.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Editorial Material
Medicine, General & Internal
Halane Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE
(2022)
Article
Medicine, General & Internal
Analia Rearte et al.
Summary: The study conducted in Argentina demonstrated that the rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines, when administered to individuals aged 60 and above, effectively reduced the risk of SARS-CoV-2 infection and COVID-19 deaths.
Article
Biochemistry & Molecular Biology
Alejandro Jara et al.
Summary: A study conducted in Chile found that administering two doses of Sinovac's inactivated SARS-CoV-2 vaccine to children aged 3-5 years, with a 28-day interval, during the Omicron outbreak, resulted in moderate effectiveness against symptomatic COVID-19 but a high level of protection against severe disease, including hospitalization and admission to the ICU.
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After administering the fourth dose of BNT162b2 vaccine to individuals aged 60 years and older during the period when the omicron variant was predominant, Israel observed lower rates of confirmed SARS-CoV-2 infection and severe Covid-19 compared to those who received only three doses. The protection against severe illness remained consistent, while the protection against confirmed infection decreased over time.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
L. J. Abu-Raddad et al.
Summary: A study in Qatar showed that booster vaccination significantly reduced the incidence of infection with the omicron variant, providing strong protection against Covid-19-related hospitalization and death. Booster effectiveness was observed for both mRNA vaccines, BNT162b2 and mRNA-1273, with lower infection rates and reduced severity of cases among those who received the booster dose.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Ori Magen et al.
Summary: The use of a fourth dose of BNT162b2 vaccine in Israel starting on January 3, 2022, has shown significant reductions in infection rate, symptomatic infection, hospitalization, and Covid-19-related deaths by February 18.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Gili Regev-Yochay et al.
Summary: Health care workers in Israel received a fourth dose of mRNA vaccine during the prevalence of the omicron variant. The fourth dose boosted antibody levels but did not surpass the maximum observed after the third dose. The vaccine demonstrated an efficacy of 31 to 43% against symptomatic disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Matthew McCallum et al.
Summary: The SARS-CoV-2 Omicron variant evades antibody-mediated immunity and exhibits enhanced affinity for host cells due to accumulation of spike mutations and remodeling of interactions with the ACE2 receptor.
Article
Immunology
Gunay Can et al.
Summary: This real-life study aimed to evaluate the association between CoronaVac vaccination and COVID-19 infections among healthcare workers, and determine its effectiveness against the alpha variant. The study found that the effectiveness of two doses of CoronaVac vaccine (39%) was lower than that determined in clinical trials. Booster doses may be needed due to reduced protection over time or against variants.
Article
Immunology
Chao Ma et al.
Summary: The study conducted two months after the vaccination campaign in Ruili demonstrated that both inactivated and Ad5 vectored vaccines have a certain effectiveness against Delta variant of COVID-19, with better protection against severe illness.
Article
Multidisciplinary Sciences
Fanglei Zuo et al.
Summary: This study demonstrates that an mRNA vaccine booster in individuals vaccinated with inactivated vaccines can significantly increase the humoral and cellular immune responses against the virus, including the Omicron variant.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, General & Internal
Wing Ying Au et al.
Summary: The study evaluates the effectiveness of heterologous and homologous COVID-19 vaccine regimens in preventing COVID-19 infections, hospital admissions, and death. Results show that a three-dose mRNA vaccine regimen is most effective against asymptomatic and symptomatic COVID-19 infections, while a homologous two-dose mRNA regimen is highly effective in preventing severe COVID-19 infections.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Medicine, General & Internal
Adam S. Lauring et al.
Summary: mRNA vaccines were highly effective in preventing covid-19 associated hospital admissions related to the alpha, delta, and omicron variants. Three vaccine doses were required for protection against omicron, while two doses provided protection against delta and alpha variants. Omicron variant showed lower disease severity compared to delta variant but still resulted in morbidity and mortality. Vaccinated patients had lower disease severity than unvaccinated patients for all the variants.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Public, Environmental & Occupational Health
Alejandro Jara et al.
Summary: This study evaluated the effectiveness of booster vaccine doses against COVID-19 in individuals who had completed a primary immunisation schedule with CoronaVac. The results showed that a homologous or heterologous booster dose provides a high level of protection against COVID-19, including severe disease and death. Heterologous boosters showed higher vaccine effectiveness than a homologous booster for all outcomes, providing additional support for a mix-and-match approach.
LANCET GLOBAL HEALTH
(2022)
Article
Immunology
Alireza Mirahmadizadeh et al.
Summary: The mass vaccination program in Iran has led to a significant reduction in COVID-19 infections, hospital admissions, and deaths associated with COVID-19.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Article
Immunology
Vladimir Petrovic et al.
Summary: This study analyzed the early effectiveness of different COVID-19 vaccines in the elderly population. The results showed that BNT162b2, BBIBP-CorV, Gam-COVID-Vac, and ChAdOx1 nCoV-19 had high effectiveness in preventing symptomatic, severe, and mild COVID-19 in the elderly, especially after full vaccination.
Article
Infectious Diseases
Pilar T. Florentino et al.
Summary: This study assessed the associations between time since two-dose vaccination with BNT162b2 and the occurrence of symptomatic SARS-CoV-2 infection and severe COVID-19 among adolescents in Brazil and Scotland. The results showed that vaccine effectiveness against symptomatic infection started to decline from 27 days after the second dose, but protection against severe COVID-19 remained high.
LANCET INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Qian Wang et al.
Summary: SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 have become dominant in the United States and South Africa, raising concerns about their ability to evade neutralizing antibodies and compromise the efficacy of COVID-19 vaccines and therapeutic monoclonals. A systematic antigenic analysis reveals that BA.2.12.1 and BA.4/5 have different levels of resistance to antibodies, with BA.2.12.1 being modestly resistant and BA.4/5 being substantially resistant. Certain mutations in the spike protein facilitate antibody escape, but compromise the spike affinity for the viral receptor. Only bebtelovimab retains full potency against both subvariants.
Article
Multidisciplinary Sciences
Nawal Al Kaabi et al.
Summary: The BBIBP-CorV (Sinopharm) vaccine has been assessed for its effectiveness against severe COVID-19 disease using data from Abu Dhabi. The vaccine showed an effectiveness of 80% against hospitalization, 86% against critical care admission, and 84% against death. However, the effectiveness declined over time, suggesting the need for booster doses to increase protection against severe COVID-19 outcomes.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Thiago Cerqueira-Silva et al.
Summary: This study evaluated the vaccine effectiveness of CoronaVac plus BNT162b2 booster during the dominance of the Omicron variant. The results showed that this vaccine combination provided durable and high protection against severe outcomes caused by the Omicron variant, except for individuals aged 80 or older.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Pilar T. Florentino et al.
Summary: Although severe COVID-19 cases in children are rare, they may experience multisystem inflammatory syndrome, long-COVID, and other effects such as social isolation and disruption of education. Limited data is available on the effectiveness of the CoronaVac vaccine during the Omicron period. A study in Brazil found that the CoronaVac vaccine had an estimated effectiveness of 39.8% against symptomatic infection and 59.2% against hospital admission in children aged 6 to 11 years at least two weeks after the second dose.
NATURE COMMUNICATIONS
(2022)
Article
Critical Care Medicine
Jing-Xin Li et al.
Summary: In a randomized controlled trial, researchers found that heterologous boost immunization with an orally administered aerosolized adenovirus-based COVID-19 vaccine is safe and highly immunogenic in adults previously primed with two doses of an inactivated COVID-19 vaccine.
LANCET RESPIRATORY MEDICINE
(2022)
Article
Immunology
Zoltan Voko et al.
Summary: The HUN-VE 3 study demonstrated the waning effectiveness of primary immunization during the Delta wave and highlighted the importance of booster vaccinations. mRNA vaccines and the Janssen vaccine showed good effectiveness after booster doses.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Rapeepong Suphanchaimat et al.
Summary: The objective of this study was to explore the real-world effectiveness of different vaccine regimens in tackling the SARS-CoV-2 Delta variant in Thailand. The study found that two-dose heterologous prime-boost regimens showed the highest level of protection and remained stable throughout the study period. Three-dose schedules were also highly effective. Heterologous prime-boost regimens appeared to provide better protection against severe infection compared to homologous regimens.
Article
Public, Environmental & Occupational Health
Yaowen Zhang et al.
Summary: This retrospective cohort study in Morocco found that Sinopharm's BBIBP-CorV vaccine is highly effective in preventing serious or critical hospitalization for COVID-19, particularly among working-age adults.
Article
Microbiology
Betul Copur et al.
Summary: This study aimed to investigate the effectiveness of CoronaVac in preventing COVID-19 among healthcare workers during the period dominated by the Alpha variant. A total of 1911 healthcare workers were included in the study. The effectiveness of CoronaVac in preventing COVID-19 was found to be 65%, with COVID-19 developing in 4.1% of double-dose vaccinated healthcare workers and 11.27% of unvaccinated healthcare workers. The findings indicate a lower effectiveness of CoronaVac against COVID-19 compared to a previous trial in Turkey, suggesting the need for mass vaccination and booster doses.
FUTURE MICROBIOLOGY
(2022)
Article
Multidisciplinary Sciences
Otavio T. Ranzani et al.
Summary: This study investigates the effectiveness of COVID-19 vaccine boosters following a primary series of CoronaVac vaccination. The study shows that boosters provide protection against severe disease, with higher effectiveness from a BNT162b2 booster compared to a CoronaVac booster. The study estimates the vaccine effectiveness (VE) of homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil during the Omicron wave. The results indicate a VE of 8.6% for symptomatic disease and 56.8% for severe COVID-19 after receiving a homologous booster, while the VE for symptomatic disease is 56.8% and for severe COVID-19 is 86.0% after receiving a heterologous booster. Waning effectiveness against severe COVID-19 is observed only after 120 days in individuals who received a homologous booster. Heterologous boosters might be preferable for individuals who have completed a primary series of inactivated vaccines.
NATURE COMMUNICATIONS
(2022)
Review
Environmental Sciences
Jie Deng et al.
Summary: Based on the available data, both homologous and heterologous COVID-19 booster doses have high effectiveness and immunogenicity, with acceptable safety. Heterologous booster doses are more effective than homologous ones, which can help inform public health decisions and reduce vaccine hesitancy.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Immunology
Vincent Ka Chun Yan et al.
Summary: Based on a case-control study using electronic health records, this research evaluated the effectiveness of CoronaVac and BNT162b2 vaccines in preventing mortality and severe complications after Omicron BA.2 infection. The study found that both vaccines were effective, and the risk of adverse outcomes decreased with the third dose, especially in individuals aged 65 and above.
EMERGING MICROBES & INFECTIONS
(2022)
Article
Biology
Maria Edith Solis-Castro et al.
Summary: This study aimed to evaluate the effectiveness of the inactivated SARS-CoV-2 (Vero Cell) vaccine used in Peru. The results showed that the vaccine had good effectiveness in reducing COVID-19 deaths and hospitalizations two weeks after receiving two doses, but had less effectiveness in preventing COVID-19 infections.
Article
Health Care Sciences & Services
Soledad Gonzalez et al.
Summary: This study evaluates the vaccine effectiveness (VE) against COVID-19-associated-hospitalisations in the 3-17-year population during the Omicron outbreak, showing high vaccine protection against associated hospitalisations in children but a decrease when Omicron became predominant.
LANCET REGIONAL HEALTH-AMERICAS
(2022)
Article
Health Care Sciences & Services
Soledad Gonzalez et al.
Summary: This study evaluated the vaccine effectiveness against COVID-19-associated hospitalisations in children aged 3-17 during the Omicron outbreak. The results showed high protection but a decrease in effectiveness when Omicron became predominant, suggesting the need for booster doses in younger children.
LANCET REGIONAL HEALTH-AMERICAS
(2022)
Article
Health Care Sciences & Services
Angel Paternina-Caicedo et al.
Summary: This study aimed to estimate the vaccine effectiveness of COVID-19 vaccines in a cohort of insured individuals over 40 years old in northern Colombia. The findings showed that CoronaVac was not effective for individuals above 80 years old, but for those aged 40-79, two doses of CoronaVac significantly reduced hospitalization, critical care admission, and death. BNT162b2 was effective for all outcomes in the population above 40 years old but declined in effectiveness for individuals aged 80 and above.
LANCET REGIONAL HEALTH-AMERICAS
(2022)
Article
Geriatrics & Gerontology
Leonardo Arregoces-Castillo et al.
Summary: This study evaluated the effectiveness of COVID-19 vaccines in preventing hospitalization and death in adults aged 60 and older in Colombia. The results showed that all analyzed vaccines were effective in preventing hospitalization and death. This is a promising outcome for the national vaccination program and other countries using these vaccines. Efforts should be made to improve vaccine coverage among older adults, and booster doses should be considered for this age group.
LANCET HEALTHY LONGEVITY
(2022)
Article
Immunology
Rafaella F. Q. Grenfell et al.
Summary: This study focuses on the effectiveness of the combination of the CoronaVac vaccine and the BNT162b2 booster in immune response. The results show that the CoronaVac vaccine increases the antibody levels, which decline after 80 days but recover after the introduction of the booster. The neutralizing antibody titers against the Delta variant are higher than those against the Omicron variant. The cellular immune response after CoronaVac vaccination releases a significant amount of chemokines, cytokines, and growth factors in the first month, which gradually decreases over time and does not increase after the booster. Individuals with prior exposure to the virus show a more robust cellular immune response and an increase in antibody levels 60 days post CoronaVac vaccination.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Daniel R. Feikin et al.
Summary: This study systematically reviewed the duration of protection provided by COVID-19 vaccines against various clinical outcomes. The findings indicate that the effectiveness or efficacy of the vaccines decreased from 1 to 6 months after full vaccination, but remained high against severe disease. Evaluating the effectiveness or efficacy of vaccines beyond 6 months is crucial for updating vaccine policies.
Article
Public, Environmental & Occupational Health
Dan Wu et al.
Summary: In an outbreak from a hospital setting, completion of primary vaccination with inactivated COVID-19 vaccines reduces the risk of symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant. Partial vaccination is ineffective, and completion of two doses of the primary vaccination is necessary for protection from Delta.
Article
Immunology
Jing Lian Suah et al.
Summary: Full vaccination with the three main vaccines in Malaysia (AZD1222, BNT162b2, and CoronaVac) has been highly effective in preventing COVID-19 infection, symptomatic COVID-19, COVID-19-related ICU admission, and death.
Article
Medicine, General & Internal
Nawal Al Kaabi et al.
Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Mine Durusu Tanriover et al.
Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.
Article
Medicine, General & Internal
Alejandro Jara et al.
Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Eddy Fadlyana et al.
Summary: The study assessed the efficacy, safety, and immunogenicity of an inactivated SARS-CoV-2 vaccine. The interim analysis showed a 65.30% efficacy in preventing COVID-19 illness, with favorable safety and immunogenicity profiles.
Article
Medicine, General & Internal
Otavio Ranzani et al.
Summary: The study evaluates the effectiveness of the CoronaVac vaccine in the elderly population aged >= 70 years in Sao Paulo state, Brazil during widespread circulation of the gamma variant. The vaccine was found to significantly reduce the risk of symptomatic covid-19, hospital admissions, and deaths after completion of the two-dose regimen, but the effectiveness decreases with age among the elderly population.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Health Care Sciences & Services
Matt D. T. Hitchings et al.
Summary: The study found that CoronaVac vaccine was effective in reducing symptomatic SARS-CoV-2 infection among healthcare workers in Manaus, especially during the Gamma variant epidemic, but the effectiveness of the two-dose schedule was low.
LANCET REGIONAL HEALTH-AMERICAS
(2021)
Review
Medicine, General & Internal
Gregory A. Poland et al.
Review
Medicine, General & Internal
Oluwatosin Wuraola Akande et al.
NIGERIAN POSTGRADUATE MEDICAL JOURNAL
(2020)
Article
Medicine, General & Internal
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL
(2011)
